Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection
Executive Summary
German giant Bayer has teamed up with investment firm Versant Ventures to launch a new stem cell company with $225m in start-up funding.
You may also be interested in...
Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
Versant's Century Aims For Off-The-Shelf Cancer Cell Therapies
With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.
Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try
Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.